Amgen Korea has announced the appointment of Shin Su-hee as its new general manager (GM), effective from Thursday.

Shin, a seasoned leader with over 25 years of experience in the pharmaceutical industry, has an extensive track record in developing and executing successful business strategies across a diverse portfolio of therapeutic areas.

Before joining Amgen Korea, Shin was the director of Roche Korea's healthcare innovation cluster, where she oversaw portfolio strategies and business performance in oncology, ophthalmology, neuroscience, and infectious diseases.

Shin also worked as the GM of the oncology division at Novartis Korea, where she launched seven new drugs.

Shin's career also includes roles at AstraZeneca Korea and Sanofi-Aventis Korea. Shin holds a Bachelor of Pharmacy degree from Ewha Womans University and an MBA from New York University's Stern School of Business.

"I am delighted to lead Amgen Korea, a pioneering biotechnology company committed to innovation," Shin said. "Aligned with Amgen's mission 'To Serve Patients,' I look forward to working with our team to continuously provide valuable solutions to patients and healthcare professionals and further establish Amgen Korea as a responsible and trusted company."

Shin succeeds Noh Sang-kyung, who has been with Amgen Korea since its inception in 2015 and is retiring at the end of July.

Under Noh's leadership, Amgen Korea has experienced significant growth and has become known for its innovative treatment solutions and patient-centered approach, where his leadership has been marked by consistent double-digit growth.